Half-year report · Q2
3055.TEDINET S100UNC6
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥141.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥275.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥135.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥884m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥730m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥884m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥730m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥149.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥147.3bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥147.6bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥88.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥86.6bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥60.8bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥60.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥58.7bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.1bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥20.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.0bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥5.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥696m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥898m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥596m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥41.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥100.2 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.35 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.6% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| Otherother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥33m |
| Otherother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Otherother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥566m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥5m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥5m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.0bn |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥289m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥712m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥22m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥34.1bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.8bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥309m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥407m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥142m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥102.8bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.6bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥750m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥147.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥141.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.9bn |
| Otherother segments | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| Otherother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥29m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| Otherother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥615m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥27m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥794m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥263m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥530m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥33m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥31.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥31.4bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥283m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥581m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥106m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥100.0bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥95.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥502m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥142.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥135.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 541
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 1408000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0669 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 1297000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0616 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 896000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0425 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 808000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0384 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 585000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0278 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 546000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0259 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 468000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0222 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 457000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0217 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 438000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0208 | |
| Number of shares held | CurrentQuarterInstant | 9586000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.4550 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 3333500 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 21052700 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 210527 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 13800 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 24400000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 210527 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 3333500 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 3333500 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.1366 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 3333500 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 3333500 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.1366 | |
| Cash and deposits | Prior1YearInstant | 20813000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 21109000000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 57409000000 | JPY |
| Notes and accounts receivable trade | CurrentQuarterInstant | 57874000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 17824000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 19125000000 | JPY |
| Work in process | Prior1YearInstant | 11000000 | JPY |
| Work in process | CurrentQuarterInstant | 28000000 | JPY |
| Other ca | Prior1YearInstant | 8084000000 | JPY |
| Other ca | CurrentQuarterInstant | 7642000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -29000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -25000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |